<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5194">
  <stage>Registered</stage>
  <submitdate>19/02/2014</submitdate>
  <approvaldate>19/02/2014</approvaldate>
  <nctid>NCT02070757</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)</studytitle>
    <scientifictitle>A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia</scientifictitle>
    <utrn />
    <trialacronym>ASPECT-NP</trialacronym>
    <secondaryid>CXA-NP-11-04</secondaryid>
    <secondaryid>7625A-008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nosocomial Pneumonia</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ceftolozane/tazobactam
Treatment: drugs - Meropenem

Experimental: Ceftolozane/tazobactam - ceftolozane/tazobactam IV 3000 mg (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days, or 14 days for Pseudomonas aeruginosa.

Active Comparator: meropenem - meropenem IV 1000 mg every 8 hours for 8-14 days, or 14 for Pseudomonas aeruginosa


Treatment: drugs: ceftolozane/tazobactam
Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(ÃŸ)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.

Treatment: drugs: Meropenem
Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All Cause Mortality - Intent-to-Treat (ITT) population</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture</outcome>
      <timepoint>TOC is 7-14 days after EOT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Day 28 all-cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) in the Microbiological Intent-to-Treat (mITT) population</outcome>
      <timepoint>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP in the Intent-to-Treat (ITT) population</outcome>
      <timepoint>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP in the Clinically Evaluable (CE) population</outcome>
      <timepoint>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Adult participants diagnosed with either VABP or ventilated HABP requiring IV
             antibiotic therapy;

          -  Intubated and on mechanical ventilation at the time of randomization;

          -  New or progressive infiltrate on chest radiography consistent with pneumonia;

          -  Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial
             pneumonia.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics;

          -  Prior non-study antibiotics for &gt; 24 hours;

          -  Gram stain of lower respiratory tract specimen showing only gram positive bacteria;

          -  Active immunosuppression;

          -  End-stage renal disease or requirement for dialysis;

          -  Expected survival &lt; 72 hours;

          -  Severe confounding respiratory condition (i.e., chest trauma with paradoxical
             respiration);

          -  Known or suspected community-acquired bacterial pneumonia.

          -  Anticipated concomitant use of any of the following medications during the course of
             study therapy: valproic acid or divalproex sodium. Anticipated concomitant use of
             serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin 5-HT1 receptor
             agonists (triptans), meperidine, or buspirone during the course of linezolid
             treatment.

          -  Receipt of a monoamine oxidase inhibitor within 14 days prior to the first dose of
             study drug or anticipated concomitant use during the course of linezolid therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>23/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>726</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>19/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Merck Sharp &amp; Dohme - North Ryde</hospital>
    <postcode> - North Ryde</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Haar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Guatemala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Hod Hasharon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hoddesdon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cubist Pharmaceuticals LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 3, multicenter, prospective, randomized study of intravenous (IV)
      ceftolozane/tazobactam vs. IV meropenem in the treatment of adult participants with either
      ventilator-associated bacterial pneumonia (VABP) or ventilated hospital-acquired bacterial
      pneumonia (HABP).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02070757</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Merck Sharp &amp; Dohme Corp.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Toll Free Number</name>
      <address />
      <phone>1-888-577-8839</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>